Category: GeneVentiv Therapeutics

GeneVentiv Therapeutics is developing the first universal gene therapy for all types of hemophilia, including the most difficult cases. By working to bring breakthrough therapies to market, this UNC-affiliated startup is also instilling expanded hope in hemophilia patients who wrestle with the daily realities of their life threatening, inherited disorder.